Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript
01:16pm, Tuesday, 14'th Oct 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) M&A Call October 14, 2025 8:00 AM EDT Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commerc
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
12:20pm, Tuesday, 14'th Oct 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?
10:01am, Tuesday, 14'th Oct 2025
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BioCryst to buy Astria Therapeutics in $700 million deal
07:35am, Tuesday, 14'th Oct 2025
BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases.
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
07:00am, Tuesday, 14'th Oct 2025
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio –
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround
10:35am, Tuesday, 07'th Oct 2025
BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 03'rd Oct 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted e
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
07:00am, Wednesday, 01'st Oct 2025
– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercializati
BioCryst: Blue Light Special In Small Cap Biotech Aisle
02:53am, Monday, 29'th Sep 2025
BioCryst Pharmaceuticals (BCRX) is highlighted for its strong potential, driven by its approved therapy ORLADEYO. BCRX's investment thesis centers on its below fair value market cap given ORLADEYO's c
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript
05:47am, Friday, 05'th Sep 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Charles Gayer - President Babar Ghias - CFO & Head of Corporat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 03'rd Sep 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
BioCryst to Present at Upcoming Investor Conference
07:00am, Thursday, 21'st Aug 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Confere
BioCryst Announces Departure of Dr. Helen Thackray
07:00am, Monday, 11'th Aug 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will lea
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 06'th Aug 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 1
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript
11:38am, Monday, 04'th Aug 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - Presi
